Walter M. Stadler to Doxorubicin
This is a "connection" page, showing publications Walter M. Stadler has written about Doxorubicin.
Connection Strength
0.611
-
Treatment of metastatic urothelial cancer in the post-MVAC era. World J Urol. 2001 Apr; 19(2):126-32.
Score: 0.184
-
Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
Score: 0.121
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.094
-
Gemcitabine doublets in advanced urothelial cancer. Semin Oncol. 2002 Feb; 29(1 Suppl 3):15-9.
Score: 0.049
-
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.
Score: 0.040
-
[New chemotherapy regimens for advanced bladder cancer]. Actas Urol Esp. 1998 Jun; 22(6):548-9.
Score: 0.038
-
New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol. 1998 Feb; 16(1):23-9.
Score: 0.037
-
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 07; 26(7):1459-64.
Score: 0.030
-
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44.
Score: 0.019